• Agomab posted a net loss of EUR 62.5 million for fiscal 2025, widening 35%.
• Operating loss widened 23% to EUR 59.3 million.
• Research and development expenses climbed 24% to EUR 48.9 million, due to progress in clinical testing for ontunisertib and AGMB-447.
• Other operating income jumped 68% to EUR 2.4 million.
• Cash, cash equivalents and cash investments totaled EUR 116.5 million at Dec. 31, 2025; existing liquidity plus IPO proceeds expected to fund operations into the first half of 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-047872), on April 23, 2026, and is solely responsible for the information contained therein.